Global Inflammatory Bowel Disease (IBD) Treatment Market Analysis Reveals TNF inhibitors As the Dominant Drug Class during the Period 2017 – 2025

Published on : Feb 21, 2018

Albany, New York, February 21, 2018: It is important to know that, inflammatory bowel disease is a group of medical indication which leads to chronic inflammation in the gastrointestinal tract. Inflammatory bowel disease primarily includes Ulcerative colitis and Crohn’s disease. The treatment for this disease is necessary and should be proceeded first hand. Presently, the global IBD treatment market is expected to be primarily driven by new product development and approvals. Further, rising utilization of biologic drugs as well as biosimilar drugs has also pushed the IBD treatment market to greater levels. In order to study the market scenario, a new report titled “Inflammatory Bowel Disease (IBD) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025”, has been included to the online repository of Market Research Hub (MRH). This research offers a clear insight about various regions contributing towards IBD treatment. Furthermore, different factors associated to the spread of inflammatory bowel disease are also covered in this assessment.

Several medications like immunomodulators, corticosteroids, as well asbiologic drugs like TNF inhibitors are recommended to revive the symptoms of these diseases. As per report findings, the high prevalence and rising incidence of Crohn’s disease as well as Ulcerative colitis disease across developed countries has motivated the development of novel therapeutics drugs. This research report includes the market definition and scope in order to enlighten the readers about the prevailing market status. Further, the executive summary and market overview can be accessed for learning about market dynamics and market size forecast for the period 2015-2025. Furthermore, pipeline analysis is also discoursed in this section.

Later on, the market segmentation can be analyzed which bifurcates the IBD treatment market into four segments, that is, drug class, distribution channel, disease indication and region. By drug class, the overall market is segmented into aminosalicyclates, TNF inhibitors, corticosteroids and immunomodulators. It has been analyzed that, the TNF inhibitors accounted for dominant share of global IBD treatment market as recorded in 2016. Further, it is projected to gain its market share by the end of 2025. By geography, the IBD treatment market is divided into North America, Europe, Latin America, Asia Pacific and Middle East & Africa. Among these, North America and Europe grabbed the leading share in the international market, and are expected to gain additional market share by 2025-end.

The final section tries to understand the major players functional in the inflammatory bowel disease treatment market. Some of these players include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc. etc.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top